(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
People with depression can treat themselves at home with new device - 2International issues on the agenda as Frances's Macron visits China
- 3Iran's stolen futures: The arrested Iranians at risk of execution by the regime
- 4Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- 5Meet the Stars of the Feline World: Well known Pet Feline Varieties
- Figure out How to Track the Establishment of New 5G Pinnacles
- How do my eyes adjust to the dark and how long does it take?
- Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- A volcanic eruption may have catalyzed the plague's arrival in Europe, study suggests
- Nestlé says 413,793 KitKat candy bars stolen en route from Italy to Poland
- Figure out How to Upgrade Your Gold Speculation Portfolio: Vital Bits of knowledge and Strategies
- Ukrainian drones hit all three Baltic States − did Russia redirect them?
- Scientists are getting our robotic explorers ready to help send humans to Mars
- Egypt seeks to calm tourist fears over fallout of Iran war
